Since the 1980s, the Gamaleya Center led the effort to develop a technological platform using adenoviruses, found in human adenoids and normally transmitting the common cold.
The Gamaleya Center successfully developed and registered in 2015 two vector-based vaccines against Ebola fever
using the adenovirus vector platform. The vaccines have been officially approved for use by the Russian
Health Ministry. About 2,000 people in Guinea received injections of Gamaleya vaccines in 2017-18.
Gamaleya Research Center received an international patent for Ebola vaccine.
References and links for registration certificates, international patents and scientific publications
about vaccines developed by the Gamaleya center
1. Gamaleya EBOLA vaccine
An Open Study of the Safety and Pharmacokinetics of a Medicinal Product for Emergency Prevention of
International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi
International patent WO2016130047A1 Immunobiological drug and method for using same for inducing
specific immunity against the Ebola virus
Russian Health Ministry registration certificates:
GamEvac-Combi is a multivalent vector-based Ebola vaccine
GamEvac-Lyo is a multivalent vector-based Ebola vaccine
GamEvac is a vector-based Ebola vaccine
Dolzhikova IV, Zubkova OV, Tukhvatulin AI, et al. Safety and immunogenicity of GamEvac-Combi, a
heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in
Russia. Hum Vaccin Immunother. 2017
Dolzhikova IV, Tokarskaya EA, Dzharullaeva AS, et al. Virus-Vectored Ebola Vaccines. Acta Naturae. 2017.
Extract from Global Advisory Committee on Vaccine Safety meeting on 5-6 June 2019, published in the
World Health Organization Weekly Epidemiological Record of 12 July 2019
Russian Foreign Ministry press release on the post-registration clinical trials of the Russian Ebola vaccine
Gam Evac Combi in Guinea.
Russia and Rusal complete Ebola vaccinations in Guinea. Pharmaceutical Technology.
2. Gamaleya MERS vaccine
Study of Safety and Immunogenicity of BVRS-GamVac
Study of Safety and Immunogenicity of BVRS-GamVac-Combi
Ozharovskaia TA, Zubkova OV, Dolzhikova IV, et al. Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein. Acta Naturae. 2019;11(1):38-47.
3. Gamaleya influenza vaccine
A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and
Immunogenicity of the GamFluVac
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
Tutykhina I, Esmagambetov I, Bagaev A, et al. Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts. Published 2018 Jan 29.
Tutykhina IL, Logunov DY, Shcherbinin DN, et al. Development of adenoviral vector-based mucosal
vaccine against influenza. 2011. J Mol Med (Berl).
Patent WO2013129961A1 Recombinant trivalent vaccine against human influenza.
4. General publications on adenoviral vector-based vaccines
Future Prospects for the Development of Cost-Effective Adenovirus Vaccines. By Cyrielle Fougeroux and Peter J. Holst
Repurposing Adenoviruses as Vectors for Vaccines.
Burmistrova DA, Tillib SV, Shcheblyakov DV, et al. Genetic Passive Immunization with Adenoviral Vector
Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma
hominis. PLoS One. 2016
Shcherbinin DN, Esmagambetov IB, Noskov AN, et al. Protective Immune Response against Bacillus
anthracis Induced by Intranasal Introduction of a Recombinant Adenovirus Expressing the Protective
Antigen Fused to the Fc-fragment of IgG2a. Acta Naturae. 2014
Tutykhina IL, Sedova ES, Gribova IY, et al. Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Res. 2013;97(3):318-328. doi:10.1016/j.antiviral.2012.12.021
Naroditsky BS, Zavizion BA, Karamov EV, Tikhonenko TI. Analysis of the genome of type 7 simian adenovirus using restrictases. Nucleic Acids Res. 1978;5(3):999-1011.
Message has been successfully sent!